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Increased Polyamine Concentrations
in the Hair of Cancer Patients
To the Editor:
Rapid tumor growth has been asso-
ciated with markedly altered poly-
amine biosynthesis and accumula-
tion (1 ), and an increase in the
concentrations of plasma and uri-
nary polyamines might provide an
independent biochemical marker of
disease activity and response to ther-
apy (2–5). However, because the
components of urine and plasma
show variations throughout the day
and because these two specimens are
rather inconvenient to obtain and
handle, another noninvasive method
for measuring polyamine concentra-
tions was required. According to re-
cent reports, hair fibers may be used
to obtain physiologic information (6–
8). Using hair samples, we have
quantified biosynthetic steroids,
which are converted from testoster-
one by 5a-reductase or cytochrome
P-450 aromatase (9, 10). We have
now investigated whether hair poly-
amine concentrations are altered in
cancer patients.
We obtained hair from 49 patients
treated at Yonsei Medical Center
from November 1998 to January
1999, including 13 individuals with
invasive cervical cancers, 11 with
ovarian carcinomas, and 25 who un-
derwent hysterectomies for benign
gynecological disease. The latter
were matched with the cancer pa-
tients for age. None of the subjects
had been treated with radiotherapy
or chemotherapy before the hair
sampling. The hair samples were ob-
tained by collecting the portions that
had been cut off during haircuts.
Hair polyamines, measured as de-
scribed elsewhere (11 ), were in-
creased in cancer patients (Table 1).
The magnitude of increase was sim-
ilar to that reported previously for
plasma and urine polyamines (2–5).
In the 25 controls, polyamine concen-
trations were ,477 ng/g of hair. In
cancer patients, polyamine concen-
trations were as high as 921 and 3998
ng/g in cervical and ovarian cases,
respectively.
Particularly in the patients with
ovarian cancer, the maximum sperm-
ine concentrations were ;10-fold
higher than those of control subjects
(Student two-tailed t-test, P ,0.001).
However, most of the patients were
still within the range of values found
in controls. Attention to this nonspe-
cific type of low polyamine concen-
trations is particularly important for
any planned use of polyamines in
cancer diagnosis, differential diagno-
sis, or screening. Clinical processes
leading to nonspecific polyamine al-
terations usually are obvious on rou-
tine physical examination or stan-
dard laboratory testing.
Our findings suggest that measur-
ing polyamines in hair may be a
simple, noninvasive technique to as-
sist in the diagnosis and assessment
of disease activity in patients with
cancer. Hair, which grows at ;1 cm/
month (12 ), reflects long-term
chronic nature with little fluctuation,
whereas blood and urine reflect the
acute status. This study may be the
starting point for additional studies
in the field of polyamine analysis,
and a study on response to therapy is
underway.
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Patients with ovarian
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54 (37–75)
Putrescine 99 6 54 ,0.001
(105; 291–179)
Spermidine 724 6 697 ,0.001
(446; 90–1699)
Spermine 1156 6 1489 ,0.001
(379; 9–3998)
a Data are expressed as mean 6 SD (median; range)
b NA, not applicable, used as the control values.
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Diagnostic Accuracy of an Agarose
Gel Electrophoretic Method in
Multiple Sclerosis
To the Editor:
In .95% of patients suffering from
clinically unambiguous multiple
sclerosis (MS), oligoclonal IgG can be
detected in cerebrospinal fluid (CSF)
(1, 2). Isoelectric focusing is the most
sensitive method for detecting oligo-
clonal bands (OCBs) (1 ), whereas
agarose gel electrophoresis is re-
ported to detect OCBs in ;80% of
cases (2 ). A commercial electro-
phoresis unit (Beckman Instruments)
is commonly used in clinical labora-
tories. Laboratory support of a clini-
cally probable diagnosis of MS in
combination with brain magnetic
resonance imaging is important to
allow initiation of appropriate treat-
ment as early as possible.
We evaluated the sensitivity of the
Beckman modified agarose gel elec-
trophoresis to detect OCB and esti-
mated its diagnostic accuracy. We
examined paired CSF and sera from
168 patients (122 females) with clini-
cally unambiguous MS (3 ) for the
presence of oligoclonal IgG.
We followed the manufacturer’s
instructions for application of sam-
ples to the buffered agarose gel (SPE-
II gel). Electrophoresis was per-
formed at 100 V for 40 min, followed
by immobilization in a fixative solu-
tion and staining. All tests were done
by the same technician and evalu-
ated by the same experienced hema-
tologist, both unaware of clinical or
magnetic resonance imaging data.
OCB was detectable in 90 of the
168 patients (53%; 95% confidence
interval, 52.9–53.1%). The mean IgG
index [(CSF-IgG/serum-IgG)/(CSF-
albumin/serum-albumin)] of OCB-
negative patients was 0.87. Patients
with detectable OCB had a mean IgG
index of 1.28 (reference value ,0.7).
This electrophoretic method does
not appear to provide adequate clin-
ical sensitivity because false-negative
results in the detection of OCB may
delay diagnosis and the start of treat-
ment.
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More on Troponin Assays and Heparin
To the Editor:
A recent article [Troponin T and I
Assays Show Decreased Concentra-
tions in Heparin Plasma Compared
with Serum: Lower Recoveries in
Early than in Late Phases of Myocar-
dial Injury (Clin Chem 2000;46:817–
21)] concluded that “Until such
methods [which are resistant to inter-
ference by both heparin and EDTA]
are available, the sample of choice for
cardiac troponin determinations is
serum collected in tubes with or
without gel, or in thrombin tubes
with and without gel”. We believe
that the conclusion is not supported
by the data presented in the article.
It is clear from the data presented
in Table 1 of the article that a bias
exists between plasma and serum
measurements for the Elecsys 2010
and the Immulite systems. No data
in the article, however, suggest that
the measured bias is related to hep-
arin. With specific reference to Table
1, the authors state that the heparin
concentrations in the tubes range
from 40 to 70 IU/mL. In their exper-
imental design, they added heparin
to serum tubes at concentrations of
50–450 IU/mL. The authors have
erroneously calculated the concen-
trations of heparin in the plasma
tubes as listed in Table 1. In fact, the
total heparin in the tubes ranges
from 40 to 70 IU to achieve a final
concentration of 14–15 IU/mL (1 ). In
calculating the heparin concentration
in the tube, the manufacturer does
not consider that blood consists of
red blood cells, which presumably
may not take up heparin. Therefore,
recalculation of the manufacturer’s
stated concentration, assuming a
40% hematocrit, gives final heparin
concentrations in the plasma of be-
tween 24 and 25 IU/mL. The associ-
ation made by the authors compar-
ing troponin concentrations measured
in serum with added heparin (50–
450 IU/mL) and in plasma from hep-
arin tubes with whole blood (24–25
IU/mL) should not be made because
the heparin concentrations are very
different and the sample matrix (se-
rum vs plasma) is different. The au-
thors state that “Therapeutic concen-
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